移动卒中单元调度对急性卒中流程参数与功能结局的影响:B_PROUD-2.0研究
B_PROUD-2.0为柏林非随机对照研究,比较疑似卒中呼叫时额外调度移动卒中单元(MSU)与仅常规救护车对急性脑缺血患者3个月功能结局的影响。B_PROUD-2.0未发现MSU调度对主要或共同主要结局有统计学显著效应,但MSU组调度后≤1小时静脉溶栓的比值更高。汇总B_PROUD-1.0与2.0分析显示对主要和共同主要结局有益。
要点
- B_PROUD-2.0中MSU调度未显著改善3个月功能结局(主要cOR 0.90,95%CI 0.72-1.14)。
- MSU组调度后≤1小时静脉溶栓的比值显著更高(OR 10.15,95%CI 7.10-14.51)。
- 汇总B_PROUD-1.0+2.0分析显示MSU调度对功能结局有益(主要cOR 0.80,95%CI 0.67-0.96)。
核心结论
- 在把握度不足的B_PROUD-2.0中,额外MSU调度未显著改善3个月功能结局。
- 汇总B_PROUD两个研究期后,MSU调度对功能结局显示有益效应。
研究设计与样本
- B_PROUD-2.0为在德国柏林开展的非随机对照研究(2019年5月至2021年4月)。
- 疑似卒中呼叫时,若有可用MSU则与常规救护车同时调度。
- B_PROUD-2.0纳入1050例平均年龄74岁、46.7%女性的脑缺血伴致残性神经症状且无再灌注治疗禁忌的患者。
- 汇总分析纳入B_PROUD-1.0主要人群后共2666例,平均年龄73岁,46.8%女性。
- 扩展队列纳入所有卒中/TIA患者共4336例,平均年龄75岁,47.6%女性。
主要发现
- B_PROUD-2.0中MSU调度对主要结局无统计学显著效应(cOR 0.90,95%CI 0.72-1.14)。
- B_PROUD-2.0中对共同主要结局无统计学显著效应(cOR 0.86,95%CI 0.63-1.17)。
- MSU组调度后≤1小时静脉溶栓的比值更高(OR 10.15,95%CI 7.10-14.51)。
- 汇总B_PROUD-1.0+2.0主要人群分析显示主要结局有益(cOR 0.80,95%CI 0.67-0.96)。
- 汇总分析显示共同主要结局有益(cOR 0.79,95%CI 0.64-0.97)。
关键数值与推荐
- B_PROUD-2.0主要结局为3个月改良Rankin量表评分(0无缺陷至6死亡)。
- 共同主要结局为3级残疾量表评分。
- 效应估计采用有序logistic回归,校正预先选择的协变量并对缺失值多重插补。
- 扩展队列中所有卒中/TIA患者的主要结局cOR 0.85(95%CI 0.75-0.95)。
- 扩展队列中所有卒中/TIA患者的共同主要结局cOR 0.86(95%CI 0.75-0.99)。
临床怎么用
- MSU调度可提高调度后≤1小时内静脉溶栓的实施比值。
- 在解释MSU对功能结局的效应时,需考虑研究把握度与实施背景。
局限性
- B_PROUD-2.0为非随机对照研究。
- COVID-19疫情与资金有限妨碍了流程改进的完全实施。
- B_PROUD-2.0实际纳入1050例,低于计划的1500例,把握度不足。
- B_PROUD-2.0提供III级证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Prehospital stroke management on mobile stroke units (MSUs) shortens time to IV thrombolysis (IVT) and improves functional outcomes. Because IVT effects are time-dependent, optimizing workflows and dispatch-related processes may enhance MSU benefits. The B_PROUD-2.0 study aimed to determine the effect of additional MSU dispatch on functional outcomes in acute stroke patients under optimized MSU organization and service delivery. METHODS: In the nonrandomized, controlled B_PROUD-2.0 study (May 2019-April 2021) conducted in Berlin, Germany, MSUs were simultaneously dispatched with conventional care ambulances for suspected stroke emergency calls, whenever available. We compared outcomes and process parameters between dispatch groups (additional MSU dispatch vs conventional care only) among patients with cerebral ischemia with disabling neurologic symptoms and no contraindications to reperfusion treatments. We used data from the Berlin dispatch center and records from the B_SPATIAL registry, consisting of 15 Berlin hospitals with stroke units. We performed pooled analyses with the B_PROUD-1.0 primary population (February 2017-April 2021) and with an extended cohort that also included patients with reperfusion treatment contraindications. The primary and co-primary outcomes were 3-month modified Rankin Scale scores (0: no deficits to 6: death) and 3-tiered disability scale scores. Effect estimates for these outcomes were obtained from ordinal logistic regressions, adjusting for a priori selected covariates after multiple imputation for missing values. RESULTS: Coronavirus disease 2019 pandemic and limited funding hindered full implementation of procedural improvements. A total of 1,050 patients (mean age: 74 years, 46.7% female) were included in B_PROUD-2.0 (vs 1,500 planned). We found no statistically significant effect of MSU dispatch on primary (common odds ratio [cOR] 0.90, 95% CI 0.72-1.14) or co-primary (cOR 0.86, 95% CI 0.63-1.17) outcomes in B_PROUD-2.0, and higher odds of IVT ≤1 hour of dispatch in the MSU group (OR 10.15, 95% CI 7.10-14.51). In pooled B_PROUD-1.0+2.0 primary population analyses (N = 2,666, mean age: 73 years, 46.8% female), we found a beneficial effect on primary (cOR 0.80, 95% CI 0.67-0.96) and co-primary (cOR 0.79, 95% CI 0.64-0.97) outcomes. The average effect on all stroke/TIA patients in the extended cohort (N = 4,336, mean age 75 years, 47.6% female) was also favorable (primary cOR 0.85, 95% CI 0.75-0.95; co-primary cOR 0.86, 95% CI 0.75-0.99). DISCUSSION: While we did not observe statistically significant differences in functional outcomes in the underpowered B_PROUD-2.0 study, we found beneficial effects considering both B_PROUD study periods, also when including all stroke/TIA patients. TRIAL REGISTRATION INFORMATION: ClinicalTrials.gov: NCT03931616. Registered: April 26, 2019. First patient enrolled: May 9, 2019. CLASSIFICATION OF EVIDENCE: The B_PROUD-2.0 study provides Class III evidence that the addition of MSUs to conventional care ambulances did not improve functional outcomes at 3 months compared with conventional care ambulances alone in patients with acute ischemic stroke.
引用
- Rohmann JL, Piccininni M, Ebinger M, et al. Effect of Mobile Stroke Unit Dispatch on Process Parameters and Functional Outcomes in Patients With Acute Stroke: The B_PROUD-2.0 Study. Neurology. 2025. PMID: 41100781. doi:10.1212/WNL.0000000000214225
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。